October 15-16, 2019, World Stem Cell Summit took place at Kerry Hotel in Pudong, Shanghai as the inaugural conference in China organized and jointly hosted by Phacilitate Leaders Asia and the Regenerative Medicine Foundation(RMF), where international experts in cell and gene therapy are brought together in China for the first time.
Experts from Asia, America, and Europe openly shared knowledge and experience, enthusiastically formed new connections, and developed partnerships towards commercialization opportunities. The event highlighted not only the immensity of the rapidly growing world-wide industry, but also the tangibility of achieving real benefits to human health with the successful collaboration of stakeholders involved in cutting-edge research and product development of cell and gene therapy.
Figure 1. Bernard Loeffk
A surprise speaker, retired US Military General Bernard Loeffke (Figure 1), gave a very spirited talk on medicine as the bridge to peace between China and the US. He reminded us of his personal involvement with forming the first US-China diplomatic relations and that such a relationship is even more critical now amidst a delicate global situation. He emphasized the need for continuing to build the bridge using the opportunities gained through collaborative efforts in medicine as an example.
JADE Biomedical took great pride as being a sponsor for the event. Founder and CEO, Dr. Claudia Lin, spoke at the conference on practical guidance on GMP quality management for the variety of cell therapies showing translational promise in laboratories and hospitals world-wide, (Figure 2).
Figure 2.Dr.Claudia Lin
Dr. Lin pointed out not only the existing challenges, but also the current opportunities in cell and gene therapy in China. She emphasized that quality is a core competency of all medicinal therapies and required for the success of products. Her talk provided a practical solution for achieving such quality by applying her coined term,“SRSQ” – System Approach, Risk Control Strategy, Scientific Rationale, and Quality Control Excellence, a concept Dr. Lin developed from her vast experience with bio-therapeutics product quality management. Dr. Lin’s talk distinctly connects the global trends and requirements in cell therapy regulation and quality management that bridge to the industry’s reality and specific challenges in China. She also offered her practical suggestions to the global cell and gene therapy community on how to reduce the gap in GMP Compliance and Quality Standards while reaping the benefits of the China market.
JADE Biomedical also hosted a booth in the conference exhibit hall for both days (Figure 3). It attracted a large percentage of the attendees at the conference. Meaningful exchanges were made and dynamic interactions at the JADE booth truly reflected the nature of JADE as being a global company with a strong footing in China. Particularly lively exchanges at the booth led by JADE’s COO David Kapitula involved Chinese, US, European, and Japanese companies regarding business collaborations and friendship.
JADE booth featured its new service: Rapid Quantitative Mycoplasma Analysis & Detection (1 day vs. 28 days) for the global cell therapy community (Figure 4). JADE’s division, JADE Bio – Pacific® Laboratories Shanghai-Suzhou, distinguishes itself with their internationally GMP Compliant Material and Product Safety Testing Services in China for global. The rapid safety method is a critical improvement for advanced cellular and gene therapies to the current available Chinese Compendium culture assay. The experts at JADE Bio-Pacific® Laboratories provide this analysis fully qualified for global submission comparable to the China, EU, and US Compendia requirements for cell therapies and biologic therapeutics.
Overall, this coming together of like-minded leaders in such an engaging, open, and collaborative environment, in the spirit of mutual understanding based on integrity and common goals, proved that there is no substitute for collective progress better than the sharing that took place at this summit.
This was one of the few truly international conferences of its caliber to ever take place in China. With their 30 years of collective experience, Phacilitate’s conference production and RMF’s world-wide leading position in cell and gene therapy advancement was well represented in this high-quality event which fulfilled its purpose and succeeded at fostering our industry’s global cause.